Groupe Francophone des Myelodysplasies
Groupe Francophone des Myelodysplasies
Explore linked clinical trials.10 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR) | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myeloproliferative Disorders, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bone marrow disorder, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Phase 2 | 2026-09-29 | NCT05768711 | |
| Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA | Hemic and Lymphatic Diseases, bone marrow disorder, hematologic disorder, myelodysplastic syndrome | Recruiting | Phase 1 / Phase 2 | 2026-09-29 | NCT05181735 | |
| Registry of Myelodysplastic Syndromes and Therapy-related Acute Myeloid Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, bone marrow disorder, hematologic disorder, leukemia, myelodysplastic syndrome, myeloid leukemia, neoplasm | Recruiting | Not stated | 2026-09-11 | NCT06956755 | |
| A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS | Hemic and Lymphatic Diseases, bone marrow disorder, hematologic disorder, myelodysplastic syndrome | Active, not recruiting | Phase 3 | 2026-09-11 | NCT03223961 | |
| Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS) | Low-risk Myelodysplastic Syndromes | Recruiting | Phase 1 | 2026-09-10 | NCT06670222 | |
| Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes | Untreated Myelodysplastic Syndrome | Active, not recruiting | Phase 1 / Phase 2 | 2026-08-11 | NCT05782127 | |
| Momelotinib in VEXAS Syndrome | Hemic and Lymphatic Diseases, VEXAS syndrome, bone marrow disorder, hematologic disorder, myelodysplastic syndrome | Recruiting | Phase 2 | 2026-08-10 | NCT07098936 | |
| IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, bone marrow disorder, hematologic disorder, leukemia, myelodysplastic syndrome, myeloid leukemia, neoplasm | Active, not recruiting | Phase 2 | 2026-08-10 | NCT03744390 | |
| IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, bone marrow disorder, hematologic disorder, leukemia, myelodysplastic syndrome, myeloid leukemia, neoplasm | Active, not recruiting | Phase 2 | 2026-08-10 | NCT03503409 | |
| Venetoclax in Patients With MDS or AML in Relapse After AHSCT | acute myeloid leukemia, myelodysplastic syndrome | Active, not recruiting | Phase 1 / Phase 2 | 2026-03-12 | NCT05226455 |